Abstract
Associations between the gut microbiome and autism spectrum disorder (ASD) have been investigated although most studies have focused on the bacterial component of the microbiome. Whether gut archaea, fungi and viruses, or function of the gut microbiome, is altered in ASD is unclear. Here we performed metagenomic sequencing on faecal samples from 1,627 children (aged 1–13 years, 24.4% female) with or without ASD, with extensive phenotype data. Integrated analyses revealed that 14 archaea, 51 bacteria, 7 fungi, 18 viruses, 27 microbial genes and 12 metabolic pathways were altered in children with ASD. Machine learning using single-kingdom panels showed area under the curve (AUC) of 0.68 to 0.87 in differentiating children with ASD from those that are neurotypical. A panel of 31 multikingdom and functional markers showed a superior diagnostic accuracy with an AUC of 0.91, with comparable performance for males and females. Accuracy of the model was predominantly driven by the biosynthesis pathways of ubiquinol-7 or thiamine diphosphate, which were less abundant in children with ASD. Collectively, our findings highlight the potential application of multikingdom and functional gut microbiota markers as non-invasive diagnostic tools in ASD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The metagenomic sequencing data generated in this study have been deposited in the NCBI Sequence Read Archive database under accession code PRJNA943687. The publicly available raw sequencing data were downloaded through the retrieved accession numbers from cited papers, including GSE113540, PRJNA516054, PRJNA782533, CRA004105, PRJEB23052 and CRA001746. Mammalian genomes including hg38, felCat8, canFam3, mm10, rn6, susScr3, galGal4 and bosTau8 are available in UCSC Genome Browser at https://genome.ucsc.edu. Bacterial plasmids, complete plastomes, UniVec sequences and reference genomes database consisting of bacterial, archaeal and viral reference genomes are available in NCBI RefSeq database at https://www.ncbi.nlm.nih.gov/refseq. Fungal reference genomes are available in NCBI RefSeq database (https://www.ncbi.nlm.nih.gov/refseq), FungiDB (http://fungidb.org) and Ensemble (http://fungi.ensembl.org). Source data are provided with this paper.
Code availability
All software used are from publicly available sources. Codes used for the microbiome analyses or figures are available via GitHub at https://github.com/qsu123/ASD_multi-kingdom_diagnosis ref. 81.
References
Lord, C., Elsabbagh, M., Baird, G. & Veenstra-Vanderweele, J. Autism spectrum disorder. Lancet 392, 508–520 (2018).
Masi, A., DeMayo, M. M., Glozier, N. & Guastella, A. J. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci. Bull. 33, 183–193 (2017).
Matin, B. K. et al. Contributing factors to healthcare costs in individuals with autism spectrum disorder: a systematic review. BMC Health Serv. Res. 22, 604 (2022).
Tordjman, S. et al. Gene × environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Front. Psychiatry 5, 53 (2014).
Geschwind, D. H. Autism: many genes, common pathways? Cell 135, 391–395 (2008).
Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 180, 568–584.e23 (2020).
Taniya, M. A. et al. Role of gut microbiome in autism spectrum disorder and its therapeutic regulation. Front. Cell. Infect. Microbiol. 12, 915701 (2022).
Wang, W. & Fu, P. Gut microbiota analysis and in silico biomarker detection of children with autism spectrum disorder across cohorts. Microorganisms 11, 291 (2023).
Wan, Y. et al. Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder. Gut 71, 910–918 (2022).
Lou, M. et al. Deviated and early unsustainable stunted development of gut microbiota in children with autism spectrum disorder. Gut 71, 1588–1599 (2022).
Liu, Z. et al. Gene variations in autism spectrum disorder are associated with alteration of gut microbiota, metabolites and cytokines. Gut Microbes 13, 1–16 (2021).
Yap, C. X. et al. Autism-related dietary preferences mediate autism–gut microbiome associations. Cell 184, 5916–5931.e17 (2021).
Jacobson, A., Yang, D., Vella, M. & Chiu, I. M. The intestinal neuro-immune axis: crosstalk between neurons, immune cells, and microbes. Mucosal Immunol. 14, 555–565 (2021).
Sharon, G. et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell 177, 1600–1618.e17 (2019).
Kang, D. W. et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5, 10 (2017).
Kang, D. W. et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci. Rep. 9, 5821 (2019).
Andreo-Martínez, P., Rubio-Aparicio, M., Sánchez-Meca, J., Veas, A. & Martínez-González, A. E. A meta-analysis of gut microbiota in children with autism. J. Autism Dev. Disord. 52, 1374–1387 (2022).
Ho, L. K. H. et al. Gut microbiota changes in children with autism spectrum disorder: a systematic review. Gut Pathog. 12, 6 (2020).
Bezawada, N., Phang, T. H., Hold, G. L. & Hansen, R. Autism spectrum disorder and the gut microbiota in children: a systematic review. Ann. Nutr. Metab. 76, 16–29 (2020).
Qu, A. et al. Children with autism show differences in the gut DNA virome compared to non-autistic children: a case control study. BMC Pediatr. 23, 174 (2023).
Weiner, A., Turjeman, S. & Koren, O. Gut microbes and host behavior: the forgotten members of the gut-microbiome. Neuropharmacology 227, 109453 (2023).
Wan, Y. et al. Alterations in fecal virome and bacteriome virome interplay in children with autism spectrum disorder. Cell Rep. Med. 5, 101409 (2024).
Gacesa, R. et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 (2022).
Vujkovic-Cvijin, I. et al. Host variables confound gut microbiota studies of human disease. Nature 587, 448–454 (2020).
Gvozdjáková, A. et al. Ubiquinol improves symptoms in children with autism. Oxid. Med. Cell. Longev. 2014, 798957 (2014).
Crane, F. L., Löw, H., Sun, I., Navas, P. & Gvozdjáková, A. Plasma membrane coenzyme Q: evidence for a role in autism. Biologics 8, 199–205 (2014).
Zhang, G. et al. Thiamine nutritional status and depressive symptoms are inversely associated among older Chinese adults. J. Nutr. 143, 53–58 (2013).
Vignisse, J. et al. Thiamine and benfotiamine prevent stress-induced suppression of hippocampal neurogenesis in mice exposed to predation without affecting brain thiamine diphosphate levels. Mol. Cell. Neurosci. 82, 126–136 (2017).
Wiley, K. D. & Gupta, M. Vitamin B1 (Thiamine) Deficiency. in StatPearls (ed. Gupta, M.) (StatPearls Publishing, 2023).
Hasler, M., Fideli, Ü. S., Susi, A. & Hisle-Gorman, E. Examining the relationship between autism spectrum disorder and neural tube defects. Congenit. Anom. 63, 100–108 (2023).
Tokatly Latzer, I. et al. Autism spectrum disorder and GABA levels in children with succinic semialdehyde dehydrogenase deficiency. Dev. Med. Child Neurol. 65, 1596–1606 (2023).
Adak, P., Banerjee, N., Sinha, S. & Bandyopadhyay, A. K. Gamma-aminobutyric acid type A receptor variants are associated with autism spectrum disorders. J. Mol. Neurosci. 73, 237–249 (2023).
Hollestein, V. et al. Excitatory/inhibitory imbalance in autism: the role of glutamate and GABA gene-sets in symptoms and cortical brain structure. Transl. Psychiatry 13, 18 (2023).
Xu, Y. et al. Leveraging existing 16S rRNA microbial data to define a composite biomarker for autism spectrum disorder. Microbiol. Spectr. 10, e0033122 (2022).
Su, Q. et al. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome. Gut Microbes 15, 2157697 (2023).
Dan, Z. et al. Altered gut microbial profile is associated with abnormal metabolism activity of Autism Spectrum Disorder. Gut Microbes 11, 1246–1267 (2020).
Kovtun, A. S., Averina, O. V., Alekseeva, M. G. & Danilenko, V. N. Antibiotic resistance genes in the gut microbiota of children with autistic spectrum disorder as possible predictors of the disease. Microb. Drug Resist. 26, 1307–1320 (2020).
Nirmalkar, K. et al. Shotgun metagenomics study suggests alteration in sulfur metabolism and oxidative stress in children with autism and improvement after microbiota transfer therapy. Int. J. Mol. Sci. 23, 13481 (2022).
Tong, Z. et al. Implications of oral streptococcal bacteriophages in autism spectrum disorder. npj Biofilms Microbiomes 8, 91 (2022).
Wang, M. et al. Alterations in gut glutamate metabolism associated with changes in gut microbiota composition in children with autism spectrum disorder. mSystems 4, e00321 (2019).
Zhang, M. et al. A quasi-paired cohort strategy reveals the impaired detoxifying function of microbes in the gut of autistic children. Sci. Adv. 6, eaba3760 (2020).
Su, Q. et al. Faecal microbiome-based machine learning for multi-class disease diagnosis. Nat. Commun. 13, 6818 (2022).
Chan, C. W. H., Leung, T. F., Choi, K. C., Tsui, S. K. W. & Chan, J. Y. W. Effects of gut microbiome and environment on the development of eczema in Chinese infants. Medicine 99, e20327 (2020).
Kang, Y., Cai, Y. & Pan, W. Change in gut microbiota for eczema: implications for novel therapeutic strategies. Allergol. Immunopathol. 46, 281–290 (2018).
Taş, E. & Ülgen, K. O. Understanding the ADHD–gut axis by metabolic network analysis. Metabolites 13, 592 (2023).
Wang, L., Xie, Z., Li, G., Li, G. & Liang, J. Two-sample Mendelian randomization analysis investigates causal associations between gut microbiota and attention deficit hyperactivity disorder. Front. Microbiol. 14, 1144851 (2023).
Anwar, A. et al. Quantitation of plasma thiamine, related metabolites and plasma protein oxidative damage markers in children with autism spectrum disorder and healthy controls. Free Radic. Res. 50, S85–s90 (2016).
Rashaid, A. H. B. et al. Profiling plasma levels of thiamine and histamine in Jordanian children with autism spectrum disorder (ASD): potential biomarkers for evaluation of ASD therapies and diet. Nutr. Neurosci. 26, 842–849 (2023).
Obrenovich, M. E., Shola, D., Schroedel, K., Agrahari, A. & Lonsdale, D. The role of trace elements, thiamin (e) and transketolase in autism and autistic spectrum disorder. Front. Biosci. 7, 229–241 (2015).
Liu, J. et al. Alteration of gut microbiota: new strategy for treating autism spectrum disorder. Front. Cell Dev. Biol. 10, 792490 (2022).
Alharthi, A., Alhazmi, S., Alburae, N. & Bahieldin, A. The human gut microbiome as a potential factor in autism spectrum disorder. Int. J. Mol. Sci. 23, 1363 (2022).
Settanni, C. R. et al. Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. Expert Rev. Gastroenterol. Hepatol. 15, 599–622 (2021).
Guidetti, C. et al. Randomized double-blind crossover study for evaluating a probiotic mixture on gastrointestinal and behavioral symptoms of autistic children. J. Clin. Med. 11, 5263 (2022).
El-Mekkawy, R. M., Hamour, N. E., Hassanein, W. A. & Allam, A. A. Evaluation of the antibacterial activity of Weissella confusa K3 cell-free supernatant against extended-spectrum βeta lactamase (ESBL) producing uropathogenic Escherichia coli U60. Saudi J. Biol. Sci. 30, 103595 (2023).
Ahmed, S. et al. The Weissella genus: clinically treatable bacteria with antimicrobial/probiotic effects on inflammation and cancer. Microorganisms 10, 2427 (2022).
Kwak, S. H., Cho, Y. M., Noh, G. M. & Om, A. S. Cancer preventive potential of kimchi lactic acid bacteria (Weissella cibaria, Lactobacillus plantarum). J. Cancer Prev. 19, 253–258 (2014).
West, K. A. et al. Multi-angle meta-analysis of the gut microbiome in autism spectrum disorder: a step toward understanding patient subgroups. Sci. Rep. 12, 17034 (2022).
Cooper, J. R. & Pincus, J. H. The role of thiamine in nervous tissue. Neurochem. Res. 4, 223–239 (1979).
Liu, N. N. et al. Multi-kingdom microbiota analyses identify bacterial–fungal interactions and biomarkers of colorectal cancer across cohorts. Nat. Microbiol. 7, 238–250 (2022).
Ananthakrishnan, A. N. et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe 21, 603–610.e3 (2017).
Morton, J. T., Donovan, S. M. & Taroncher-Oldenburg, G. Decoupling diet from microbiome dynamics results in model mis-specification that implicitly annuls potential associations between the microbiome and disease phenotypes—ruling out any role of the microbiome in autism (Yap et al. 2021) likely a premature conclusion. Preprint at bioRxiv https://doi.org/10.1101/2022.02.25.482051 (2022).
Rolland, T. et al. Phenotypic effects of genetic variants associated with autism. Nat. Med. 29, 1671–1680 (2023).
First, M. B. Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J. Nerv. Ment. Dis. 201, 727–729 (2013).
Wong, P. P., Wai, V. C., Chan, R. W., Leung, C. N. & Leung, P. W. Autism-spectrum quotient-child and autism-spectrum quotient-adolescent in Chinese population: screening autism spectrum disorder against attention-deficit/hyperactivity disorder and typically developing peers. Autism 25, 1913–1923 (2021).
Pappas, D. ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. J. Psychoeduc. Assess. 24, 172–178 (2006).
Memória, C. M. et al. Applicability of the Test of Variables of Attention - T.O.V.A in Brazilian adults. Dement. Neuropsychol. 12, 394–401 (2018).
Hanifin, J. M. & Rajka, G. Diagnostic features of atopic dermatitis. Acta Derm. Venereol. 60, 44–47 (1980).
Tito, R. Y. et al. Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development. Nat. Med. 30, 1339–1348 (2024).
Chumpitazi, B. P. et al. Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol. Motil. 28, 443–448 (2016).
Chen, Z. et al. Impact of preservation method and 16S rRNA hypervariable region on gut microbiota profiling. mSystems 4, e00271-18 (2019).
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Lu, J. et al. Metagenome analysis using the Kraken software suite. Nat. Protoc. 17, 2815–2839 (2022).
Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. Genome Biol. 20, 257 (2019).
Marçais, G. & Kingsford, C. A fast, lock-free approach for efficient parallel counting of occurrences of k-mers. Bioinformatics 27, 764–770 (2011).
Lu, J., Breitwieser, F. P., Thielen, P. & Salzberg, S. L. Bracken: estimating species abundance in metagenomics data. PeerJ Comput. Sci. 3, e104 (2017).
van den Boogaart, K. G. & Tolosana-Delgado, R. “compositions”: a unified R package to analyze compositional data. Comput. Geosci. 34, 320–338 (2008).
Dixon, P. VEGAN, a package of R functions for community ecology. J. Veg. Sci. 14, 927–930 (2003).
Ma, S. et al. Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin. Genome Biol. 23, 208 (2022).
Mallick, H. et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput. Biol. 17, e1009442 (2021).
Su, Q. ASD_multi-kingdom_diagnosis. GitHub https://github.com/qsu123/ASD_multi-kingdom_diagnosis (2024).
Acknowledgements
We thank F. Mo, C. Shea and C. Ho for facilitating the clinical participants’ enrolment. This study was supported by InnoHK (F.K.L.C, S.C.N.), the Government of Hong Kong, Special Administrative Region of the People’s Republic of China, The D. H. Chen Foundation (F.K.L.C., S.C.N.), and the New Cornerstone Science Foundation through the New Cornerstone Investigator Program (S.C.N.).
Author information
Authors and Affiliations
Contributions
Q.S. and O.W.H.W. conceived the study, ran analyses and drafted the paper. W.L., Y.W., L.Z., W.X., M.K.T.L., C.L. and T.F.L. contributed to part of metagenomic sequencing. C.P.C., J.Y.L.C. and P.K.C. contributed to participant recruitment, sample collection and biobank management. S.C. and P.L. contributed to participant recruitment and clinical assessment. F.K.L.C. contributed to the study design and data interpretation. S.C.N. oversaw the entire study and contributed to the study design, data analysis and interpretation, and paper writing. All authors gave final approval for the version to be published.
Corresponding author
Ethics declarations
Competing interests
F.K.L.C. is a Board Member of CUHK Medical Centre. He is a co-founder, non-executive Board Chairman, honorary Chief Medical Officer and shareholder of GenieBiome Ltd. He receives patent royalties through his affiliated institutions. He has received fees as an advisor and honoraria as a speaker for Eisai Co. Ltd., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Co., and Takeda (China) Holdings Co. Ltd. S.C.N. has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda. She has received research grants through her affiliated institutions from Olympus, Ferring, and Abbvie, and is a scientific co-founder and shareholder of GenieBiome Ltd. She also receives patent royalties through her affiliated institutions. Q.S., L.Z., Y.W., F.K.L.C. and S.C.N. are named inventors of patent applications (no. 63/533,871, US, 2023) held by the CUHK and MagIC that cover the therapeutic and diagnostic use of microbiome. The remaining authors declare no competing interests.
Peer review
Peer review information
Nature Microbiology thanks Ivan Vujkovic-Cvijin and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Overview of microbial composition in four kingdoms across cohorts.
a, Composition of archaea, bacteria and fungi was shown at phylum level and composition of virus was shown at family level. Top 5 abundant phyla or families are shown in the pie chart and others are summed into others. b, Principal components analysis of gut microbiome composition across different cohorts. c, Differential taxa across different cohorts identified by MaAsLin2.
Extended Data Fig. 2 The influence of individual phenotypic factor on the multi-kingdom microbiome (archaea, bacteria, fungi and viruses) composition assessed by multivariate PERMANOVA analysis (two-sided test) in the discovery cohort (709 ASD and 374 NT).
Phenotypic factors with a significant (p < 0.05) influence on each kingdom were marked with *. ASD, autism spectrum disorder; NT, neurotypical.
Extended Data Fig. 3 The influence of individual phenotypic factor on the microbiome function (KO genes and MetaCyc pathways) assessed by multivariate PERMANOVA analysis (two-sided test) in the discovery cohort (709 ASD and 374 NT).
Phenotypic factors with a significant (p < 0.05) influence on each kingdom were marked with *. KO, Kyoto Encyclopedia of Genes and Genomes orthology. ASD, autism spectrum disorder; NT, neurotypical.
Extended Data Fig. 4 Matched confounders between ASD (n = 301) and NT (n = 301) in the balanced sub-cohort constructed by one-by-one pairing algorithm, including age (a), BMI (b), sex (c), sequencing batch (d), GI parameters (e) and dietary factors (f).
Continuous data were compared using two-sided Mann-Whitney U test (two-sided test) and shown via the median (centre line), 25th and 75th percentiles (box limits) and the 5th and 95th percentiles (whiskers). Categorical variables were presented as proportions and were compared using two-sided Chi-squire test or Fisher’s exact test (expected count<5). Dietary patterns were assessed by principal components analysis. BMI, body mass index; GI, gastrointestinal. ASD, autism spectrum disorder; NT, neurotypical.
Extended Data Fig. 5 Validation of trained models in children under 6 years of age (14 ASD and 17 NT) in the independent hospital cohort.
AUC were calculated after adjustment for technical factors and available covariates including age, sex, body mass index, Bristol stool form scale, functional constipation and defecation disorders. ASD, autism spectrum disorder; NT, neurotypical.
Extended Data Fig. 6 Associations between ASD and 31 markers in the independent community cohort (stratified by age) assessed by MaAsLin 2 (two-sided test).
The Coef value of each association was only marked when p value less than 0.05. ASD, autism spectrum disorder; NT, neurotypical.
Extended Data Fig. 7 Validation of model using 31 markers on the public dataset.
a, Construction of an external validation cohort of ASD from six published studies. b, Area under the Curve of model using 31 markers tested in the public dataset. AUC were calculated after adjustment for available covariates from public datasets including age, sex, and batch effects (defined by different studies). P values were calculated by Wilcoxon rank-sum test (two-sided test). ASD, autism spectrum disorder; NT, neurotypical.
Extended Data Fig. 8 Decreased abundance of ubiquinol-7 and thiamine diphosphate biosynthesis genes in ASD children across different cohorts.
Associations between ubiquinol-7 and thiamine diphosphate biosynthesis genes and ASD were assessed by MaAsLin 2 (two-sided test). The Coef value of each association was only marked when p value less than 0.05. ASD, autism spectrum disorder; NT, neurotypical.
Supplementary information
Source data
Source Data Fig. 1
Statistical source data.
Source Data Fig. 2
Statistical source data.
Source Data Fig. 3
Statistical source data.
Source Data Fig. 4
Statistical source data.
Source Data Extended Data Fig. 2
Statistical source data.
Source Data Extended Data Fig. 3
Statistical source data.
Source Data Extended Data Fig. 4
Statistical source data.
Source Data Extended Data Fig. 5
Statistical source data.
Source Data Extended Data Fig. 6
Statistical source data.
Source Data Extended Data Fig. 7
Statistical source data.
Source Data Extended Data Fig. 8
Statistical source data.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Su, Q., Wong, O.W.H., Lu, W. et al. Multikingdom and functional gut microbiota markers for autism spectrum disorder. Nat Microbiol 9, 2344–2355 (2024). https://doi.org/10.1038/s41564-024-01739-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41564-024-01739-1